Comparison
NMN vs Omega-3 (DHA/EPA)
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
| Field | NMN | Omega-3 (DHA/EPA) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 1000–3000mg |
| Half-life | — | 24h |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●● |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 600 | 5200 |
The comparison in plain English
Auto-generated from dataNMN and Omega-3 (DHA/EPA) are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function.
Bottom line
NMN (evidence B, safety 5/5) has a stronger evidence base than Omega-3 (DHA/EPA) (evidence A, safety 5/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.